Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity of Fractional Dose of the HPV Vaccines
NCT05291871Phase 4Active, not recruiting
- Sponsor
- University of Washington
- Start
- Jun 2022
- Primary completion
- Dec 2026
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 4 trial of human papillomavirus vaccine in human papillomavirus infection, sponsored by University of Washington. Started Jun 2022; status: active, not recruiting.
02
Drugs
human papillomavirus vaccine
03
Conditions
human papillomavirus infection
Beyond the preview
Go deeper on NCT05291871.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05291871.